Abstract
Adenoviruses (Ads) are arguably one of the most potent viruses for in vivo gene therapy, vaccine, and oncolytic applications. The attraction for the use of Ads stems from their ability to infect a wide range of dividing and non-dividing cell types in some cases to efficiencies of nearly 100%. Additional benefits include their stability, the ability to purify the vector to concentrations of up to 1013 particles/ml, and the fact that viral vectors self-assemble into particles of specific size (~100 nm). The vast majority of clinical applications of Ad have utilized Ad serotype 5 (Ad5) viruses. Considering that at least half of humans are already immune to Ad5, Ad5 oncolytics may not be optimal for clinical translation. Given this and that there are 54 different serotypes of human Ads, this review considers the utility of "mining" these alternate Ad serotypes for viruses that can evade Ad5 immunity and kill different types of cancer.
Keywords: Adenovirus, oncolytic, cancer, serotypes, liver damage, immunevasion, in vivo gene therapy, vector, serotypes
Current Pharmaceutical Biotechnology
Title:Mining the Adenovirus "Virome" for Systemic Oncolytics
Volume: 13 Issue: 9
Author(s): Michael A. Barry, Eric A. Weaver and Christopher Y. Chen
Affiliation:
Keywords: Adenovirus, oncolytic, cancer, serotypes, liver damage, immunevasion, in vivo gene therapy, vector, serotypes
Abstract: Adenoviruses (Ads) are arguably one of the most potent viruses for in vivo gene therapy, vaccine, and oncolytic applications. The attraction for the use of Ads stems from their ability to infect a wide range of dividing and non-dividing cell types in some cases to efficiencies of nearly 100%. Additional benefits include their stability, the ability to purify the vector to concentrations of up to 1013 particles/ml, and the fact that viral vectors self-assemble into particles of specific size (~100 nm). The vast majority of clinical applications of Ad have utilized Ad serotype 5 (Ad5) viruses. Considering that at least half of humans are already immune to Ad5, Ad5 oncolytics may not be optimal for clinical translation. Given this and that there are 54 different serotypes of human Ads, this review considers the utility of "mining" these alternate Ad serotypes for viruses that can evade Ad5 immunity and kill different types of cancer.
Export Options
About this article
Cite this article as:
A. Barry Michael, A. Weaver Eric and Y. Chen Christopher, Mining the Adenovirus "Virome" for Systemic Oncolytics, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958823
DOI https://dx.doi.org/10.2174/138920112800958823 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry Effects of Edible Algae Polysaccharides on Allergic, Inflammatory, and Anti-Tumor Responses Through Toll-Like Receptor 4
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets Cornea: Window to Ocular Immunology
Current Immunology Reviews (Discontinued) Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy
Current Pharmaceutical Biotechnology Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Transcriptome Analysis of FEN1 Knockdown HEK293T Cell Strain Reveals Alteration in Nucleic Acid Metabolism, Virus Infection, Cell Morphogenesis and Cancer Development
Combinatorial Chemistry & High Throughput Screening Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Understanding the Molecular Mechanisms of Betel miRNAs on Human Health
MicroRNA